Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Metrics to compare | AARD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAARDPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.2x | −0.1x | −0.5x | |
PEG Ratio | 0.05 | 0.00 | 0.00 | |
Price/Book | −3.5x | 0.2x | 2.6x | |
Price / LTM Sales | - | 0.7x | 2.9x | |
Upside (Analyst Target) | 215.7% | 433.3% | 51.4% | |
Fair Value Upside | Unlock | 6.4% | 9.5% | Unlock |